Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 17/20 | 1.00 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682154 | 1.00 | SLC6A4 (1.00) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL7207923 | 0.92 | SLC6A4 (0.85) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL7740609 | 0.90 | SLC6A4 (0.82) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL7066491 | 0.89 | SLC6A4 (1.00) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL6943295 | 0.89 | SLC6A4 (0.80) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL7065556 | 0.89 | SLC6A4 (0.80) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL7736779 | 0.88 | SLC6A4 (0.79) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL3362794 | 0.88 | SLC6A4 (0.79) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL6955114 | 0.87 | SLC6A4 (0.78) | SLC6A4SOS1SLC6A3SLC6A2 | |
| SCHEMBL3361913 | 0.87 | SLC6A4 (0.77) | SLC6A4SOS1SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054688-A1 | Selective serotonin reuptake inhibitors in the treatment of disease | PFIZER INC | 2005-03-10 | — | — | US | claimed |
| WO-2005013984-A1 | SELECTIVE SEROTONIN REUPTAKE INHIBITORS FOR THE TREATMENT OF PREMATURE FEMALE ORGASM | PFIZER LIMITED (GB) | 2005-02-17 | — | — | WO | claimed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | claimed |
| EP-1313701-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2003-05-28 | — | — | EP | claimed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002018333-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-03-07 | — | — | WO | claimed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2017-04-27 | — | — | US | disclosed |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LIMITED (CY) | 2016-08-18 | — | — | US | disclosed |
| US-9394278-B2 | Substituted triazole derivatives as oxytocin antagonists | IXCHELSIS LIMITED (GB) | 2016-07-19 | — | — | US | disclosed |
| US-9193969-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2015-11-24 | — | — | US | disclosed |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2015-11-12 | — | — | US | disclosed |
| US-20050026810-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005006899-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004020414-A1 | OXYTOCIN INHIBITORS | PFIZER LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1313701-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2003-05-28 | — | — | EP | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002018333-A1 | PHENOXYBENZYLAMINE DERIVATIVES AS SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054688-A1 | Selective serotonin reuptake inhibitors in the treatment of disease | HTR5A, HTR1A, HTR3B | SLC6A4 5/4885SOS1 2068/4885SLC6A3 21/4885 |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SLC6A4 5/4885SOS1 839/4885SLC6A3 3/4885 |
| US-20170114040-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | SLC6A4 679/4885SOS1 3469/4885SLC6A3 198/4885 |
| US-20160235856-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | SLC6A2, SLC18A2, SLC1A1 | SLC6A4 8/4885SOS1 3266/4885SLC6A3 6/4885 |
| US-20150322042-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | OXTR, AVPR1B, GNRHR | SLC6A4 679/4885SOS1 3469/4885SLC6A3 198/4885 |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | SLC6A4 3126/4885SOS1 2095/4885SLC6A3 4037/4885 |
| US-10150752-B2 | Substituted triazole derivatives as oxytocin antagonists | OXTR, AVPR1B, GNRHR | SLC6A4 679/4885SOS1 3469/4885SLC6A3 198/4885 |
| US-20050026810-A1 | Treatment of male sexual dysfunction | AVPR1A, AVPR1B, AVPR2 | SLC6A4 44/4885SOS1 4654/4885SLC6A3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.